Pressmeddelande -
VISCOGEL RECEIVES RESEARCH GRANT FROM THE EU FOR PROJECT IN THE VACCINE FIELD
Viscogel AB has received a research grant of EUR 1.2 million under the EU FP7 program for the ViVac project coordinated by the company. The main project objective is to clinically investigate the adjuvant effect of ViscoGel® in prophylactic vaccination. The project consortium consists of leading European biotechnology companies and research institutes.
The ViVac project has two objectives. The main objective is to clinically investigate the safety and efficacy of ViscoGel®, Viscogel AB’s unique proprietary chitosan-gel, as an adjuvant in prophylactic vaccination. The second objective is to pre-clinically evaluate the efficacy in therapeutic allergy vaccination. The total project budget is EUR 1.5 million and the grant from the EU finances approximately 80% of the project.
”The grant from the EU provides important financial support to our pre-clinical and clinical development program. We also get an opportunity to benefit from collaborating with the best academic and industry experts in the field through the consortium”, said Peter Singer, the CEO of Viscogel AB. ”We view the grant as a recognition of the scientific value of our development projects and our strategy”.
Viscogel AB has shown in Proof-of-Concept studies in animals that ViscoGel® as an adjuvant induced rapid and improved immune responses, which is the basis for the ViVac project. The ViVac project consortium has expertise from academia and industry. It includes in addition to Viscogel AB: Lytix Biopharma AS (Norway), Inmunotek SL (Spain), NTNU (Norway), Hacettepe University (Turkey), Huntingdon Life Sciences (UK), Karolinska Institute (Sweden) and Stallergenes SA (France).
The global vaccine market was estimated at USD 21 billion in 2008 with an expected annual growth rate of 12%. An adjuvant is an agent added to a vaccine to increase the efficacy of the vaccine. The demand for new adjuvants is high as there are few adjuvants currently available for use in the market.
Contact:
Peter Singer, CEO
Telephone: +46 (0)708 - 555 100
E-mail: peter.singer@viscogel.se
Ämnen
- Medicin, läkemedel
Kategorier
- research grant
- adjuvant
- viscogel
- therapeutic allergy vaccination
- eu grant
- eu fp7
- vivac
- prophylactic vaccination
About Viscogel AB
Viscogel AB was founded in 2008 to further develop a novel high quality chitosan and viscoelastic gels for medical applications. The company has a unique expertise in chitosan and has developed Viscosan®, which is a medical grade chitosan of a quality previously not available in the market. The company has also patented a novel viscoelastic chitosan hydrogel - ViscoGel® - which can be mechanically processed to small particles. The particles have a large surface area available for interaction with the immune system, enable a rapid and improved immune response and can be injected. Viscogel AB is owned by the founders, management and private investors.
For more information: See attached Media Brief document or visit www.viscogel.se
Viscogel AB
